A Phase 1/2 interventional study of Combined Bupivacaine and Exparel and Normal Saline (NS) in Pain, Postoperative, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by The University of Texas Health Science Center, Houston · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston — 1 open to participants now, 1 under way, none of them phase 3. Pain, Postoperative · The University of Texas Health Science Center, Houston.
Among the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1/2, and was the 18th registered.
5,675 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →1 of the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston is open now, in 1 country.
By country, each count listing its studies:
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 55 across the 16 interventional studies, 667 across the 2 observational. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Pain, Postoperative by The University of Texas Health Science Center, Houston, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare recovery unit and post operation day (POD) 1 pain score in women following elective robotic assisted TLH (RA-TLH) for benign indication with and without local vaginal cuff injection of short acting bupivacaine and long acting Exparel, to evaluate postoperative pain management and control by assessing the amount and frequency of NSAIDS and opioids taken and to assess bleeding, vaginal discharge and or vaginal dehiscence at the postoperative follow up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Combined Bupivacaine and Exparel
Drug: Normal Saline (NS)
In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will receive 20 cc of a mixture of 40 cc of short term 0.25% bupivacaine hydrochloride and long term 20 mL of Exparel® (266 mg/20 mL) mixed with 100cc of normal saline (total amount 160 cc) to the vaginal cuff using William's cystoscopy needle. The mixture will be infiltrated evenly at the uterosacral ligament with care (10 cc on each uterosacral ligament) taken to distribute the injection across the full length of the cuff at the end of the procedure.
In addition to the Laparoscopic Transversus Abdominis Plane (TAP) Block, participants will get will get vaginal cuff infiltration with 20 cc of injectable NS at the end of the procedure.
Change in pain as assessed by the visual analog scale (VAS)
Pain will be scored from 1-10 , higher number indicating more pain
Time frame: 4-6 hours post operation, postoperative day 1, postoperative day 3
Change in level of pain control achieved as assessed by the amount of nonsteroidal anti-inflammatory drugs (NSAIDs) needed
Time frame: 2-week and 6- week follow up
Change in level of pain control achieved as assessed by the frequency of NSAIDS needed
Time frame: 2-week and 6- week follow up
Change in level of pain control achieved as assessed by the amount of opioids needed
Time frame: 2-week and 6- week follow up
Change in level of pain control achieved as assessed by the frequency of opioids needed
Time frame: 2-week and 6- week follow up
Change in level of bleeding as assessed by the volume of blood loss reported by the surgeon
Time frame: 2-week and 6- week follow up
Change in presence of vaginal dehiscence
This will be categorically reported as a yes or no answer
Time frame: 2-week and 6- week follow up
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2028, 18 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston →